Device attaches directly to damaged heart, enabling delivery of multiple therapy doses

June 11, 2018, Massachusetts Institute of Technology
'Therepi' device attaches to heart
Therepi's reservoir, which would attach directly to the damaged heart tissue, is placed on a dime for size reference and connected to a self-sealing subcutaneous port. Credit: Nature Biomedical Engineering, Whyte et al.

After a patient has a heart attack, a cascade of events leading to heart failure begins. Damage to the area in the heart where a blood vessel was blocked leads to scar tissue. In response to scarring, the heart will remodel to compensate. This process often ends in ventricular or valve failure.

A team of researchers is hoping to halt the progression from attack to with a small device called 'Therepi.' The device contains a reservoir that attaches directly to the damaged heart tissue. A refill line connects the reservoir to a port on or under the patient's skin where therapies can be injected either by the patient or a healthcare professional.

A new study published in Nature Biomedical Engineering involving a team of researchers from MIT, Harvard University, Royal College of Surgeons in Ireland, Trinity College Dublin, Advanced Materials and BioEngineering Research (AMBER) Centre, and National University of Ireland Galway details how Therepi can be used to restore cardiac function.

"After a we could use this device to deliver therapy to prevent a patient from getting heart failure," explains Ellen Roche, co-first author of the study and assistant professor at MIT's Department of Mechanical Engineering and MIT's Institute for Medical Engineering and Science. "If the patient already has some degree of heart failure, we can use the device to attenuate the progression."

Two of the most common systems currently used for delivering therapies to prevent heart failure are inefficient and invasive. In one method, drugs are delivered systemically rather than being administered directly to the site of the damage. The volume of drugs used has to be limited to avoid toxic side effects and often only a small amount reaches the damaged heart tissue.

"From a pharmacological point-of-view, it's a big problem that you're injecting something that doesn't stay at the damaged tissue long enough to make a difference," says William Whyte, co-first author and Ph.D. candidate at Trinity College Dublin and AMBER.

The alternative method involves an invasive procedure to directly inject therapies into the heart muscle. Since multiple doses are needed, this requires multiple invasive surgeries.

Therepi looks like a small patch and can be sutured onto tissue, in this case, a heart. Credit: Second Bay Studios/Harvard SEAS

Therepi addresses the problems with current drug delivery methods by administering localized, non-invasive therapies as many times as needed. The device's reservoir can be implanted on the heart in just one surgical procedure.

Localized, bespoke therapies

The reservoir itself holds amazing potential for drug delivery. Constructed out of a gelatin-based polymer, the reservoir has a half-spherical shape with a flat bottom attached to the diseased tissue. The flat bottom consists of a semi-permeable membrane that can be adjusted to allow more drugs or larger materials to pass directly into the heart tissue.

"The material we used to construct the reservoir was crucial. We needed it to act like a sponge so it could retain the therapy exactly where you need it," adds Whyte. "That is difficult to accomplish since the heart is constantly squeezing and moving."

The reservoir provides a unique opportunity for administering stem cell therapies. It acts as a cell factory. Rather than pass through the membrane into the heart, the cells stay within the reservoir where they produce paracrine factors that promote healing in the damaged .

In a rat model, the device was shown to be effective in improving cardiac function after a heart attack. The researchers administered multiple doses of cells to a damaged heart throughout a four-week period. They then analyzed the hemodynamic changes in the tissue using a pressure volume catheter and used echocardiography to compare functional changes over time.

Therepi's reservoir can be connected to a port or pump via a tube when it needs to be refilled. Credit: Second Bay Studios/Harvard SEAS

"We saw that the groups that had our device had recovered some heart function," explains Claudia Varela, a Ph.D. student in the Harvard-MIT Division of Health Sciences and Technology.

The hearts that received multiple dosages of cells via had more than those who received only a single injection or no treatment at all.

Finding the Optimal Dose

Therepi's capabilities go beyond treating heart disease. Since it provides the opportunity for multiple, localized doses to be delivered, it could be used as a tool to identify the exact dosage appropriate for a host of conditions.

"We are hoping to use the device itself as a research tool to learn more about the optimal drug loading regime," says Roche.

For the first time, researchers could have an opportunity to track multiple refills of localized therapies over time to help identify the best dosing intervals and dose amount.

"As a pharmacist by training, I'm really excited to start investigating what the best dose is, when is the best time to deliver after a heart attack, and how many doses are needed to achieve the desired therapeutic effect," adds Whyte.

While the team has been focusing on how Therepi can mitigate the effects of heart disease, the device could be used in other parts of the body. By optimizing the design and adjusting the materials used to construct the reservoir, Therepi could be used for a wide range of diseases and health problems.

"The is really a platform that can be tailored to different organ systems and different conditions," says Varela. "It's just a great example of how intersectional research looking at both devices and biological therapies can help us come up with new ways to treat disease."

Explore further: Investigational heart failure therapy seeks to stimulate body's natural healing response

More information: Sustained release of targeted cardiac therapy with a replenishable implanted epicardial reservoir, Nature Biomedical Engineering (2018). DOI: 10.1038/s41551-018-0247-5 , https://www.nature.com/articles/s41551-018-0247-5

Related Stories

Investigational heart failure therapy seeks to stimulate body's natural healing response

May 2, 2018
The University of Minnesota is the first institution in the state to participate in the phase III clinical trial for CardiAmp Therapy. Previous clinical studies of this therapy have been promising and have shown improvements ...

Vitamin D may help prevent heart failure after heart attack

March 8, 2018
New research has shown how vitamin D may help protect heart tissue and prevent heart failure after a heart attack, potentially offering a low-cost addition to existing treatments for heart failure.

New study finds knocking out p63 gene as means of converting scar tissue into muscle tissue in the heart

April 17, 2018
Following a heart attack, the parts of the heart muscle that die do not regenerate into new heart tissue and instead are replaced by scar tissue. Using rodent models, researchers at Baylor College of Medicine are looking ...

Extreme makeover of the heart: Matrix therapy is first FDA-approved procedure of its kind

September 17, 2015
A cardiovascular team at University of Utah Hospital has successfully performed a first-in-the-world heart procedure on a 72-year-old attorney after suffering a large heart attack. Amit N. Patel, M.D. M.S., director of clinical ...

Linking heart attack damage to the spleen and kidney, an integrated study of heart failure

November 15, 2017
Heart failure after a heart attack is a global epidemic leading to chronic heart failure pathology. About 6 million people in the United States and 23 million worldwide suffer from this end-stage disease.

Stem cell patch shows early promise in treating heart failure

April 5, 2017
Patching a damaged heart with a patient's own muscle stem cells improves symptoms of heart failure, according to a Phase I clinical trial reported in Journal of the American Heart Association, the Open Access Journal of the ...

Recommended for you

'Smart stent' detects narrowing of arteries

June 19, 2018
For every three individuals who have had a stent implanted to keep clogged arteries open and prevent a heart attack, at least one will experience restenosis—the renewed narrowing of the artery due to plaque buildup or scarring—which ...

Marriage may protect against heart disease / stroke and associated risk of death

June 18, 2018
Marriage may protect against the development of heart disease/stroke as well as influencing who is more likely to die of it, suggests a pooled analysis of the available data, published online in the journal Heart.

Deaths from cardiac arrest are misclassified, overestimated

June 18, 2018
Forty percent of deaths attributed to cardiac arrest are not sudden or unexpected, and nearly half of the remainder are not arrhythmic—the only situation in which CPR and defibrillators are effective—according to an analysis ...

Tick-borne meat sensitivity linked to heart disease

June 15, 2018
University of Virginia School of Medicine researchers have linked sensitivity to an allergen in red meat—a sensitivity spread by tick bites—with a buildup of fatty plaque in the arteries of the heart. This buildup may ...

Tobacco aside, e-cigarette flavorings may harm blood vessels

June 14, 2018
Flavor additives used in electronic cigarettes and related tobacco products could impair blood vessel function and may be an early indicator of heart damage, according to new laboratory research in Arteriosclerosis, Thrombosis ...

The molecules that energize babies' hearts

June 14, 2018
A metabolic process that provides heart muscle with energy fails to mature in newborns with thickened heart walls, according to a Japan–Canada research team.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym786622
not rated yet Jun 12, 2018
I was diagnosed with COPD 5 years ago and was taking Spiriva and Advair plus nose sprays to slow down progression. My symptoms have always been shortness of breath, and dizziness. I am a 54 year old female. the Spiriva wasn't really working and I could not tolerate them for long due to severe side effects, so this year our family doctor started me on Natural Herbal Gardens COPD Herbal mixture, We ordered their COPD herbal treatment after reading alot of positive reviews, i am happy to report with the help of Natural Herbal Garden natural herbs I have been able to reverse my symptoms using herbs, my symptoms totally declined over a 9 weeks use of the Natural Herbal Gardens COPD natural herbal formula. My COPD is totally reversed! Their official web page is www . naturalherbalgardens . com After the herbal treatment I also finally was able to give up smoking after 20 years. I 'm thankful to nature

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.